Peptide Therapeutics Market Cost Structures, Growth rate and Industry Analysis to 2027

1. Peptide Therapeutics Market To Reach USD 50.60 Billion By 2026

2. Market Summary Increased incidence of cancer, presence of active product range, cumulative acceptance of sedentary lifestyle leading to rising of metabolic diseases, emerging healthcare markets, are key factors contributing to high CAGR of Peptide Therapeutics market during the forecast period. Market Size – USD 25.35 Billion in 2018, Market Growth - CAGR of 9.0%, Market Trends– Advancements in Peptide Conjugates, and technological innovations in Peptide Therapeutics.

3. Our Approach Our Approach Market Summary The global Peptide Therapeutics market was valued at USD 25.35 billion in 2018 and is expected to reach USD 50.60 billion by the year 2026, at a CAGR of 9.0%. Peptide drugs are used as replacement therapies which supplements peptide hormones when the endogenous levels tend to decrease. The first peptide therapeutic was used to treat diabetic patients in the 19th century. The approval for 60 peptides has been granted, with the clinical global administration in the United States, Europe, and Japan. These drugs are used as drug target moiety for cancer, metabolic disorders, cardiovascular disease. To improve efficiency, conjugates became a boon to alter the properties of proteins. The Polyethylene Glycol (PEG) conjugation, lipids, and proteins have been used for extending the half-life. penetrating peptides, termed as ideal transporters, are responsible for assisting the therapeutic cargos in a non- toxic and simple manner being protein, oligonucleotides, nanoparticles. They are currently used in cancer therapy due to its potent and quick delivery. In recent years, cell- Specific problems and restraints are shown by peptide therapeutics. The drawbacks are short plasma life and the inability of the functioning of oral bioavailability. By increasing the drug stability and peptide formulation, the peptide therapeutics can be taken in an oral form quickly. Request for a sample of this research report @ https://www.reportsanddata.com/sample-enquiry-form/2770

4. Our Approach Our Approach Market Summary Further key findings from the report suggest • The peptide therapeutics market is expected to reach USD 50.59 billion by the year 2026 at a CAGR of 9.0%, according to the forecast period. • Kallyope, a U.S based company, and Novo Nordisk, a Denmark based Company, entered into a research collaboration and agreement to discover novel therapeutics for treating obesity and diabetes in June 2018. • North America has the largest market share of 38.2% in the year 2018. Its increased dominance in the market is due to the increased investments of Research and Development, high incidence of cancer, and increased demand for healthcare expenditure. The advent of Peptide conjugates will also further drive a rapid increase in the market. • The solid-phase peptide synthesis is expected to reach USD 22.6 billion by the year 2026, showing a good growth market in the year 2026. • Hybrid technology is expected to grow with a CAGR of 8.8% in 2026. To identify the key trends in the industry, click on the link below: https://www.reportsanddata.com/report-detail/peptide-therapeutics-market

5. Our Approach Our Approach Market Summary Key participants include Sanofi (Australia), Teva Inc (Israel), Novo Nordisk Inc, (Denmark), Takeda (Japan), Eli Lily (United States), Astra Zeneca (U.K.), Novartis (Switzerland), Shire (U.S.) Abbvie (U.S.), Ipsen (France) Allergen (Ireland ), Ferring (Switzerland), Merck (United States), The Medicines (United States), Roche (Switzerland) Johnson and Johnson (United States). For the purpose of this report, Reports and Data has segmented the Peptide Therapeutics market based on Route of Administration, Product Type, Type of Manufacturers, Application, Synthesis, Regional Outlook: Route of Administration (Revenue in Million USD; 2016–2026) Parenteral Route Oral Route Pulmonary Mucosal Others Product Type Outlook (Revenue in Million USD; 2016–2026) Generic Innovative

6. Our Approach Our Approach Market Summary Application Outlook (Revenue in Million USD; 2016–2026) Cancers Metabolic Cardiovascular Disorder Respiratory GIT Anti-infection Pain Dermatology CNS Renal Others Order Now: https://www.reportsanddata.com/checkout-form/2770

7. About Us Our Approach Our Approach About Us About Us Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise. Contact Us: John Watson Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com